Metabolic Effects of Pioglitazone in Type II Diabetic Patients Previously Treated With Insulin

• Status: Completed
• Trial end date: 2007-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of the study is to demonstrate whether a switch from insulin therapy to an oral therapy with pioglitazone/glimepiride will lead to a deterioration of glycemic control (increase in HbA1c by more than 0.5 %) within a 6 month observation period.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: IKFE Institute for Clinical Research and Development
• Treatments: Glimepiride; Insulin; Insulin, Globin Zinc; Pioglitazone

Criteria

Inclusion Criteria:

• type 2 diabetes mellitus

• insulin therapy > 1 year

• residual ß-cell function (C-peptide increase in iv glucagon test)

• written informed consent

Exclusion Criteria:

• type 1 diabetes

• oral therapy

• life-threatening disease

• heart failure (NYHA I-IV)